Bausch Health Co. Inc. (BHC) Q4 Revenue Tops Views, Guidance Misses at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Bausch Health Companies (BHC) PT Lowered to $25 at BMO Capital
February 21, 2019 9:35 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Bausch Health Companies (NYSE: BHC) to $25.00 (from $26.00) while maintaining a Market Perform rating.
Nachman notes BHC delivered relatively in-line 4Q and 2019 guidance overall roughly in-line with expectations, although bottom-end of revenue range... More
